Foghorn Therapeutics Inc. (FHTX) — 8-K Filings

8-K Filings (30)

• 8-K Filing — May 7, 2026
• Foghorn Therapeutics Announces Board and Executive Changes — Dec 4, 2025 Risk: low
  Foghorn Therapeutics Inc. announced on December 3, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company re
• Foghorn Therapeutics Files 8-K — Nov 7, 2025 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on November 7, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details th
• Foghorn Therapeutics Files 8-K — Oct 30, 2025 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on October 30, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, o
• 8-K Filing — Sep 2, 2025
• 8-K Filing — Jul 1, 2025
• Foghorn Therapeutics Files 8-K for Security Holder Vote — Jun 17, 2025 Risk: medium
  On June 17, 2025, Foghorn Therapeutics Inc. filed an 8-K report to announce a submission of matters to a vote of its security holders. The filing does not discl
• Foghorn Therapeutics: Director Departure, New Officer, Comp Changes — May 1, 2025 Risk: medium
  Foghorn Therapeutics Inc. announced on April 25, 2025, the departure of Director David Epstein and the election of new Director David R. Johnson. The company al
• Foghorn Therapeutics Files 8-K — Apr 28, 2025 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on April 28, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Othe
• Foghorn Therapeutics Files 8-K — Mar 24, 2025 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on March 24, 2025, reporting current information. The filing indicates the company's principal executive offices are loca
• Foghorn Therapeutics Files 8-K — Mar 20, 2025 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on March 20, 2025, reporting other events and financial statements. The filing does not contain specific details on new a
• Foghorn Therapeutics Files 8-K — Feb 3, 2025 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on February 3, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
• Foghorn Therapeutics Faces Nasdaq Listing Rule Violation — Jan 24, 2025 Risk: medium
  Foghorn Therapeutics Inc. announced on January 23, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet a continued listing
• Foghorn Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation
• Foghorn Therapeutics Announces Director Departure, New Appointments — Dec 30, 2024 Risk: medium
  Foghorn Therapeutics Inc. announced on December 29, 2024, the departure of Director Jeffrey J. Astrachan. The company also elected new directors and appointed n
• Foghorn Therapeutics Files 8-K — Dec 16, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on December 16, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, O
• Foghorn Therapeutics Files 8-K on Financials — Nov 4, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation
• Foghorn Therapeutics Files 8-K — Oct 10, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on October 10, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, o
• Foghorn Therapeutics Files 8-K on Security Holder Votes — Jun 26, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on June 26, 2024, to report on the submission of matters to a vote of security holders. The filing does not contain detai
• Foghorn Therapeutics Files 8-K — Jun 3, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Merck to Acquire Foghorn Therapeutics for $300M — May 23, 2024 Risk: medium
  Foghorn Therapeutics Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $300 million in cas
• Foghorn Therapeutics Files 8-K: Material Agreement & Other Events — May 22, 2024 Risk: medium
  On May 20, 2024, Foghorn Therapeutics Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements a
• Foghorn Therapeutics Files 8-K — May 20, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on May 20, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Foghorn Therapeutics Appoints New CMO, Discloses Officer Compensation — Apr 16, 2024 Risk: medium
  Foghorn Therapeutics Inc. announced on April 16, 2024, the appointment of Dr. Jeffrey W. Allen as Chief Medical Officer and the departure of Dr. Adrian S. Law a
• Foghorn Therapeutics Files 8-K — Apr 9, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on April 9, 2024, to report on several events. The filing includes a Regulation FD Disclosure, other events, and financia
• Foghorn Therapeutics Files 8-K — Mar 7, 2024 Risk: low
  Foghorn Therapeutics Inc. filed an 8-K on March 7, 2024, to report on its results of operations and financial condition, as well as to provide Regulation FD dis
• Foghorn Therapeutics Files 8-K on Reg FD Disclosure, Other Events — Feb 8, 2024 Risk: medium
  Foghorn Therapeutics Inc. filed an 8-K on February 8, 2024, to report a Regulation FD Disclosure and Other Events. This filing indicates that the company is pro
• Foghorn Therapeutics Files Routine 8-K on Jan 16 Event — Jan 17, 2024
  Foghorn Therapeutics Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024. This filing is a standard current report under
• Foghorn Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — Jan 8, 2024
  Foghorn Therapeutics Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its registration on The Nasdaq Global Market un
• Foghorn Therapeutics Reports Officer/Director Changes, Comp Arrangements — Jan 3, 2024
  Foghorn Therapeutics Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on December 29, 2023. This filing indicates changes related to 'Depa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX